Key Points
- Ascendis Pharma CFO Scott Thomas Smith bought 100 shares on June 2 at $219 each, a $21,900 transaction that increased his holdings by 2.34% to 4,367 shares.
- The stock last traded at $216.60, with a 52-week range of $160.86 to $250.74, and the company has a market value of about $13.51 billion.
- Analysts remain broadly positive on ASND, with an average Buy rating and a consensus price target of $295.39; the company most recently beat EPS estimates but missed revenue expectations.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) CFO Scott Thomas Smith acquired 100 shares of the firm's stock in a transaction on Tuesday, June 2nd. The stock was bought at an average price of $219.00 per share, for a total transaction of $21,900.00. Following the completion of the acquisition, the chief financial officer owned 4,367 shares of the company's stock, valued at approximately $956,373. The trade was a 2.34% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.
Ascendis Pharma A/S Price Performance
NASDAQ:ASND opened at $216.60 on Wednesday. Ascendis Pharma A/S has a one year low of $160.86 and a one year high of $250.74. The company has a market cap of $13.51 billion, a P/E ratio of 24.98 and a beta of 0.39. The firm's fifty day moving average price is $233.43 and its two-hundred day moving average price is $223.39. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.00 and a quick ratio of 0.72.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.21 by $0.11. The company had revenue of $285.45 million during the quarter, compared to analyst estimates of $362.47 million. Equities analysts expect that Ascendis Pharma A/S will post 11.72 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the stock. Wolfe Research restated an "outperform" rating and issued a $260.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Wedbush restated an "outperform" rating and issued a $273.00 price target on shares of Ascendis Pharma A/S in a research note on Thursday, April 9th. Evercore restated an "outperform" rating and issued a $329.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Bank of America upped their price target on shares of Ascendis Pharma A/S from $262.00 to $292.00 and gave the company a "buy" rating in a research note on Thursday, April 16th. Finally, Jefferies Financial Group assumed coverage on shares of Ascendis Pharma A/S in a research note on Monday, March 16th. They issued a "buy" rating and a $290.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $295.39.
Check Out Our Latest Research Report on ASND
Hedge Funds Weigh In On Ascendis Pharma A/S
Several hedge funds and other institutional investors have recently made changes to their positions in ASND. Advisory Services Network LLC acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at approximately $26,000. Arax Advisory Partners raised its position in shares of Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company's stock valued at $33,000 after buying an additional 104 shares in the last quarter. Leonteq Securities AG acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at approximately $42,000. Finally, Jones Financial Companies Lllp raised its position in shares of Ascendis Pharma A/S by 57.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company's stock valued at $44,000 after buying an additional 83 shares in the last quarter.
About Ascendis Pharma A/S
(
Get Free Report)
Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.
The company's lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
